Cargando…
Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome
SIMPLE SUMMARY: Chronic inflammation is known to drive cancer initiation and progression in the liver and other organs. In different genetic mouse models, the role of the pro-inflammatory kinase Tak1 in liver cancer development has been controversial so far. To clarify the role of Tak1 in human hepa...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774263/ https://www.ncbi.nlm.nih.gov/pubmed/35053591 http://dx.doi.org/10.3390/cancers14020430 |
_version_ | 1784636295456227328 |
---|---|
author | Ridder, Dirk Andreas Urbansky, Lana Louisa Witzel, Hagen Roland Schindeldecker, Mario Weinmann, Arndt Berndt, Kristina Gerber, Tiemo Sven Köhler, Bruno Christian Nichetti, Federico Ludt, Annekathrin Gehrke, Nadine Schattenberg, Jörn Markus Heinrich, Stefan Roth, Wilfried Straub, Beate Katharina |
author_facet | Ridder, Dirk Andreas Urbansky, Lana Louisa Witzel, Hagen Roland Schindeldecker, Mario Weinmann, Arndt Berndt, Kristina Gerber, Tiemo Sven Köhler, Bruno Christian Nichetti, Federico Ludt, Annekathrin Gehrke, Nadine Schattenberg, Jörn Markus Heinrich, Stefan Roth, Wilfried Straub, Beate Katharina |
author_sort | Ridder, Dirk Andreas |
collection | PubMed |
description | SIMPLE SUMMARY: Chronic inflammation is known to drive cancer initiation and progression in the liver and other organs. In different genetic mouse models, the role of the pro-inflammatory kinase Tak1 in liver cancer development has been controversial so far. To clarify the role of Tak1 in human hepatocellular carcinoma (HCC), we investigated the expression of Tak1 in a large and clinicopathologically well-characterized patient cohort with HCC. In human livers and HCCs, Tak1 is predominantly present in its isoform Tak1A localizing to the cell nucleus. Tak1 is upregulated in HCCs of the diethylnitrosamine mouse model as well as in human HCCs, independent of etiology, and is further induced in distant metastases. Overexpression of the isoform Tak1A in the HCC cell line Huh7 resulted in increased tumor cell migration, whereas overexpression of full-length Tak1 had no significant effect. In human HCCs, high nuclear Tak1 expression is associated with vascular invasion and short overall survival. ABSTRACT: Although knowledge on inflammatory signaling pathways driving cancer initiation and progression has been increasing, molecular mechanisms in hepatocarcinogenesis are still far from being completely understood. Hepatocyte-specific deletion of the MAPKKK Tak1 in mice recapitulates important steps of hepatocellular carcinoma (HCC) development, including the occurrence of cell death, steatohepatitis, dysplastic nodules, and HCCs. However, overactivation of Tak1 in mice upon deletion of its deubiquitinase Cyld also results in steatohepatitis and HCC development. To investigate Tak1 and Cyld in human HCCs, we created a tissue microarray to analyze their expression by immunohistochemistry in a large and well-characterized cohort of 871 HCCs of 561 patients. In the human liver and HCC, Tak1 is predominantly present as its isoform Tak1A and predominantly localizes to cell nuclei. Tak1 is upregulated in diethylnitrosamine-induced mouse HCCs as well as in human HCCs independent of etiology and is further induced in distant metastases. A high nuclear Tak1 expression is associated with short survival and vascular invasion. When we overexpressed Tak1A in Huh7 cells, we observed increased tumor cell migration, whereas overexpression of full-length Tak1 had no significant effect. A combined score of low Cyld and high Tak1 expression was an independent prognostic marker in a multivariate Cox regression model. |
format | Online Article Text |
id | pubmed-8774263 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87742632022-01-21 Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome Ridder, Dirk Andreas Urbansky, Lana Louisa Witzel, Hagen Roland Schindeldecker, Mario Weinmann, Arndt Berndt, Kristina Gerber, Tiemo Sven Köhler, Bruno Christian Nichetti, Federico Ludt, Annekathrin Gehrke, Nadine Schattenberg, Jörn Markus Heinrich, Stefan Roth, Wilfried Straub, Beate Katharina Cancers (Basel) Article SIMPLE SUMMARY: Chronic inflammation is known to drive cancer initiation and progression in the liver and other organs. In different genetic mouse models, the role of the pro-inflammatory kinase Tak1 in liver cancer development has been controversial so far. To clarify the role of Tak1 in human hepatocellular carcinoma (HCC), we investigated the expression of Tak1 in a large and clinicopathologically well-characterized patient cohort with HCC. In human livers and HCCs, Tak1 is predominantly present in its isoform Tak1A localizing to the cell nucleus. Tak1 is upregulated in HCCs of the diethylnitrosamine mouse model as well as in human HCCs, independent of etiology, and is further induced in distant metastases. Overexpression of the isoform Tak1A in the HCC cell line Huh7 resulted in increased tumor cell migration, whereas overexpression of full-length Tak1 had no significant effect. In human HCCs, high nuclear Tak1 expression is associated with vascular invasion and short overall survival. ABSTRACT: Although knowledge on inflammatory signaling pathways driving cancer initiation and progression has been increasing, molecular mechanisms in hepatocarcinogenesis are still far from being completely understood. Hepatocyte-specific deletion of the MAPKKK Tak1 in mice recapitulates important steps of hepatocellular carcinoma (HCC) development, including the occurrence of cell death, steatohepatitis, dysplastic nodules, and HCCs. However, overactivation of Tak1 in mice upon deletion of its deubiquitinase Cyld also results in steatohepatitis and HCC development. To investigate Tak1 and Cyld in human HCCs, we created a tissue microarray to analyze their expression by immunohistochemistry in a large and well-characterized cohort of 871 HCCs of 561 patients. In the human liver and HCC, Tak1 is predominantly present as its isoform Tak1A and predominantly localizes to cell nuclei. Tak1 is upregulated in diethylnitrosamine-induced mouse HCCs as well as in human HCCs independent of etiology and is further induced in distant metastases. A high nuclear Tak1 expression is associated with short survival and vascular invasion. When we overexpressed Tak1A in Huh7 cells, we observed increased tumor cell migration, whereas overexpression of full-length Tak1 had no significant effect. A combined score of low Cyld and high Tak1 expression was an independent prognostic marker in a multivariate Cox regression model. MDPI 2022-01-15 /pmc/articles/PMC8774263/ /pubmed/35053591 http://dx.doi.org/10.3390/cancers14020430 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ridder, Dirk Andreas Urbansky, Lana Louisa Witzel, Hagen Roland Schindeldecker, Mario Weinmann, Arndt Berndt, Kristina Gerber, Tiemo Sven Köhler, Bruno Christian Nichetti, Federico Ludt, Annekathrin Gehrke, Nadine Schattenberg, Jörn Markus Heinrich, Stefan Roth, Wilfried Straub, Beate Katharina Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome |
title | Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome |
title_full | Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome |
title_fullStr | Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome |
title_full_unstemmed | Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome |
title_short | Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome |
title_sort | transforming growth factor-β activated kinase 1 (tak1) is activated in hepatocellular carcinoma, mediates tumor progression, and predicts unfavorable outcome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774263/ https://www.ncbi.nlm.nih.gov/pubmed/35053591 http://dx.doi.org/10.3390/cancers14020430 |
work_keys_str_mv | AT ridderdirkandreas transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome AT urbanskylanalouisa transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome AT witzelhagenroland transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome AT schindeldeckermario transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome AT weinmannarndt transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome AT berndtkristina transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome AT gerbertiemosven transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome AT kohlerbrunochristian transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome AT nichettifederico transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome AT ludtannekathrin transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome AT gehrkenadine transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome AT schattenbergjornmarkus transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome AT heinrichstefan transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome AT rothwilfried transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome AT straubbeatekatharina transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome |